SIGNPATH PHARMA, INC. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2023-03-03: Study NCT05768919; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Recruiting.
- 2014-03: Study NCT02138955; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Completed.
- 2011-08: Study NCT01403545; Company role Lead sponsor; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2023-03-03 | NCT05768919 Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas | Lead sponsor | Phase 1, Phase 2 | Recruiting | Glioblastoma | 30 | 2027-05 |
| 2014-03 | NCT02138955 A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer | Lead sponsor | Phase 1, Phase 2 | Completed | Patients w/Advanced Cancer That Failed Std of Care Therapy | 30 | 2018-02-15 |
| 2011-08 | NCT01403545 Evaluation of Liposomal Curcumin in Healthy Volunteers | Lead sponsor | Phase 1 | Completed | Drug Safety | 50 | 2012-08 |